Core Viewpoint - Dechipher Pharmaceuticals (06996) experienced a significant stock increase of approximately 14% following the announcement of its drug ATG-022 receiving breakthrough therapy designation from the National Medical Products Administration for treating CLDN18.2 positive, HER2 negative unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma [1] Group 1: Stock Performance - Dechipher Pharmaceuticals' stock rose by 14.18%, reaching HKD 6.28, with a trading volume of HKD 21.1499 million [1] Group 2: Drug Development and Market Potential - ATG-022 has been granted breakthrough therapy designation for specific gastric cancer patients, indicating its potential significance in the market [1] - CCB International raised its long-term and peak sales forecast for ATG-022 by nearly 30% and adjusted the company's DCF target price to HKD 8.8, corresponding to a target market value of approximately HKD 6 billion and a peak sales revenue multiple of 2.1x [1] Group 3: Analyst Insights - Goldman Sachs noted that the updated Phase II data for Dechipher Pharmaceuticals in the context of unresectable or metastatic gastric cancer is encouraging, with an increase in patient numbers and extended follow-up time [1] - The firm believes that the efficacy and safety of ATG-022 remain competitive, with the median progression-free survival (mPFS) being a key focus for future updates, which could impact competitor comparisons and potential accelerated approval pathways [1]
港股异动 | 德琪医药(06996)早盘涨近14% ATG-022竞争力有望加强 机构上调中长期及峰值销售